Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release: Novartis announces Tabrecta(R) -2-

06/04/2021 | 09:05am EDT
patients treated with TABRECTA live longer or if their symptoms improve. 
There are ongoing studies to find out how TABRECTA works over a longer 
period of time. 
   It is not known if TABRECTA is safe and effective in children. 
   Important Safety Information 
   TABRECTA may cause serious side effects, such as lung or breathing 
problems. TABRECTA may cause inflammation of the lungs during treatment 
that may lead to death. Patients should be advised to contact their 
health care provider right away if they develop any new or worsening 
symptoms, including cough, fever, trouble breathing, or shortness of 
   TABRECTA may cause abnormal blood test results, which may be a sign of 
liver problems. Patients should be advised that their health care 
provider will do blood tests to check their liver before starting and 
during treatment with TABRECTA. Patients should be advised to contact 
their health care provider right away if they develop any signs and 
symptoms of liver problems including the skin or the white part of their 
eyes turning yellow (jaundice), dark or "tea-colored" urine, 
light-colored stools (bowel movements), confusion, loss of appetite for 
several days or longer, nausea and vomiting, pain, aching, or tenderness 
on the right side of the stomach area (abdomen), or weakness or swelling 
in the stomach area. 
   The skin may be sensitive to the sun (photosensitivity) during treatment 
with TABRECTA. Patients should be advised to use sunscreen or wear 
clothes that cover their skin during treatment with TABRECTA to limit 
direct sunlight exposure. 
   For women of reproductive potential, TABRECTA can harm their unborn 
baby. They should use an effective method of birth control during 
treatment with TABRECTA and for 1 week after the last dose. Men who have 
partners who can become pregnant should use effective birth control 
during treatment with TABRECTA and for 1 week after the last dose. 
   Before taking TABRECTA, patients should tell their health care provider 
about all their medical conditions, including if they have or have had 
lung or breathing problems other than lung cancer, have or have had 
liver problems, or if they are pregnant or plan to become pregnant, as 
TABRECTA can harm their unborn babies. Females who are able to become 
pregnant should have a pregnancy test before they start treatment with 
TABRECTA and should use effective birth control during treatment and for 
1 week after the last dose of TABRECTA. Patients should be advised to 
talk to their health care provider about birth control choices that 
might be right for them during this time and to tell their health care 
provider right away if they become pregnant or think they may be 
pregnant during treatment with TABRECTA. Males who have female partners 
who can become pregnant should use effective birth control during 
treatment and for 1 week after their last dose of TABRECTA. 
   Patients should tell their health care provider about all the medicines 
they take or start taking, including prescription and over-the-counter 
medicines, vitamins, and herbal supplements. 
   The most common side effects of TABRECTA include swollen hands, ankles, 
or feet (peripheral edema); nausea and/or vomiting; tiredness and/or 
weakness (fatigue, asthenia); shortness of breath (dyspnea); loss of 
appetite; changes in bowel movements (diarrhea or constipation); cough; 
pain in the chest; fever (pyrexia); back pain; and decreased weight. 
   Please see full Prescribing Information for Tabrecta available at : 
   This press release contains forward-looking statements within the 
meaning of the United States Private Securities Litigation Reform Act of 
1995. Forward-looking statements can generally be identified by words 
such as "potential," "can," "will," "plan," "may," "could," "would," 
"expect," "anticipate," "seek," "look forward," "believe," "committed," 
"investigational," "pipeline," "launch," or similar terms, or by express 
or implied discussions regarding potential marketing approvals, new 
indications or labeling for the investigational or approved products 
described in this press release, or regarding potential future revenues 
from such products. You should not place undue reliance on these 
statements. Such forward-looking statements are based on our current 
beliefs and expectations regarding future events, and are subject to 
significant known and unknown risks and uncertainties. Should one or 
more of these risks or uncertainties materialize, or should underlying 
assumptions prove incorrect, actual results may vary materially from 
those set forth in the forward-looking statements. There can be no 
guarantee that the investigational or approved products described in 
this press release will be submitted or approved for sale or for any 
additional indications or labeling in any market, or at any particular 
time. Nor can there be any guarantee that such products will be 
commercially successful in the future. In particular, our expectations 
regarding such products could be affected by, among other things, the 
uncertainties inherent in research and development, including clinical 
trial results and additional analysis of existing clinical data; 
regulatory actions or delays or government regulation generally; global 
trends toward health care cost containment, including government, payor 
and general public pricing and reimbursement pressures and requirements 
for increased pricing transparency; our ability to obtain or maintain 
proprietary intellectual property protection; the particular prescribing 
preferences of physicians and patients; general political, economic and 
business conditions, including the effects of and efforts to mitigate 
pandemic diseases such as COVID-19; safety, quality, data integrity or 
manufacturing issues; potential or actual data security and data privacy 
breaches, or disruptions of our information technology systems, and 
other risks and factors referred to in Novartis AG's current Form 20-F 
on file with the US Securities and Exchange Commission. Novartis is 
providing the information in this press release as of this date and does 
not undertake any obligation to update any forward-looking statements 
contained in this press release as a result of new information, future 
events or otherwise. 
   About Novartis 
   Novartis is reimagining medicine to improve and extend people's lives. 
As a leading global medicines company, we use innovative science and 
digital technologies to create transformative treatments in areas of 
great medical need. In our quest to find new medicines, we consistently 
rank among the world's top companies investing in research and 
development. Novartis products reach nearly 800 million people globally 
and we are finding innovative ways to expand access to our latest 
treatments. About 110,000 people of more than 140 nationalities work at 
Novartis around the world. Find out more at https://www.novartis.com/. 
   Novartis is on Twitter. Sign up to follow @Novartis at 
https://twitter.com/novartisnews https://twitter.com/novartisnews 
   For Novartis multimedia content, please visit 
   For questions about the site or required registration, please contact 
   1. ClinicalTrials.gov. A Study of Capmatinib (INC280) in NSCLC Patients With 
      MET Exon 14 Alterations Who Have Received Prior MET Inhibitor. (2016). 
      Available at: https://clinicaltrials.gov/ct2/show/NCT02750215. Accessed 
      March 2021. 
   2. Wolf, J. et.al. Capmatinib in MET exon 14-mutated, advanced NSCLC: 
      updated results from the GEOMETRY mono-1 study. Abstract #9020. 2021 
      American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 
      Chicago, IL. 
   3. Wolf, J. et.al. Patient-reported outcomes in capmatinib-treated patients 
      with METex14- mutated advanced NSCLC: Results from the phase II GEOMETRY 
      mono-1 study. Abstract #9056. 2021 American Society of Clinical Oncology 
      (ASCO) Annual Meeting, June 4-8, Chicago, IL. 
   4. IQVIA. Weekly / Daily Module Views- Rx Weekly (NPA). Accessed April 5, 
   5. Siegel R, Miller K, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 
   6. Rami-Porta R, Asamura H, Traves W, et al. Lung cancer -- major changes in 
      the American Joint Committee on Cancer eight edition cancer staging 
      manual. CA Cancer J Clin. 2017;67:138. 
   7. Tsang ES, et al. Clinical outcomes after whole-genome sequencing in 
      patients with metastatic non-small cell lung cancer. Cold Spring Harb Mol 
      Case Stud. 2019.5:a002659. 
   8. Shea M, et. al. Management of advanced non-small cell lung cancers with 
      known mutations or rearrangements: latest evidence and treatment 
      approaches. Therapeutic Advances in Respiratory Disease. 2016;10(2) 
   9. Salgia R. MET in lung cancer: biomarker selection based on scientific 
      rationale. Molecular Cancer Therapeutics. 2017;16(4):555-565. 
  10. Cappuzzo F, Marchetti A, Rossi E. Increased MET gene copy number 
      negatively affects survival of surgically resected non-small-cell lung 
      cancer patients. J Clin Oncol. 2009;27:1667-1674. 
  11. Tong JH, Yeung SF, Chan Al. MET amplification and exon 14 splice site 
      mutation define unique molecular subgroups of on-small cell lung 
      carcinoma with poor prognosis. Clin Cancer Res. 2016;22:3048-3056. 
  12. Heist, RS, et.al. Capmatinib efficacy in patients with NSCLC identified 
      as METex14 using an NGS based liquid biopsy assay: results from the 
      GEOMETRY mono-1 study. Abstract #9111. 2021 American Society of Clinical 
      Oncology (ASCO) Annual Meeting, June 4-8, Chicago, IL. 
  13. Juergen Wolf, M.D., et al. Capmatinib in METex14-Mutated or MET-Amplified 

(MORE TO FOLLOW) Dow Jones Newswires

June 04, 2021 09:05 ET (13:05 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.00% 34928.48 Delayed Quote.14.14%
IQVIA HOLDINGS INC. -0.34% 246.88 Delayed Quote.38.25%
NOVARTIS AG -0.13% 83.77 Delayed Quote.0.28%
RS PUBLIC COMPANY LIMITED -1.07% 18.5 End-of-day quote.6.94%
YRC WORLDWIDE INC. 0.77% 5.23 Delayed Quote.17.38%
All news about NOVARTIS AG
11:34aIONIS PHARMACEUTICALS : Says Phase 3 Trial of Pelacarsen for Reducing Recurrent ..
07/29Rubius Therapeutics Taps Dannielle Appelhans as Chief Operating Officer
07/28XOMA : Secures FDA's Orphan Drug Designation for Investigational Pancreatic Canc..
07/28GLOBAL MARKETS LIVE : Apple, Alphabet, Facebook, Pfizer, McDonald's...
07/28XOMA Gets Orphan Drug Designation for Pancreatic Cancer Treatment
07/28NOVARTIS AG : Sell rating from JP Morgan
07/27NOVARTIS : Gets US FDA's Orphan Drug Designation For Pancreatic Cancer Treatment
07/27NOVARTIS : Morgan Stanley Lowers Price Target on Novartis, Maintains Overweight/..
07/27NOVARTIS AG : Gets a Buy rating from Morgan Stanley
07/27Artios raises USD153m in Series C financing
More news
Financials (USD)
Sales 2021 51 962 M - -
Net income 2021 9 849 M - -
Net Debt 2021 22 988 M - -
P/E ratio 2021 20,5x
Yield 2021 3,53%
Capitalization 226 B 226 B -
EV / Sales 2021 4,78x
EV / Sales 2022 4,47x
Nbr of Employees 109 000
Free-Float 87,4%
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 92,64 $
Average target price 105,56 $
Spread / Average Target 13,9%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG0.28%225 343
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVO NORDISK A/S35.94%212 048